NeoStem (AMEX:NBS) announced Thursday that as part of its ongoing parternship with the Vatican's Pontifical Council for Culture (PCC), designed to advance adult stem cell research, it will host a conference on the subject at the Vatican.
In a press conference today, both NeoStem and the PCC announced the event is scheduled for November 9 - 11, 2011.
The partnership, originally forged in May 2010, is intended to advance the use adult stem cells by fostering scientific research and exploring the cultural, ethical and human implications of their use.
The November conference, driven by NeoStem's charitable Stem for Life Foundation and the Council's Science Theology and the Ontological Quest International, will feature experts in adult stem cell research.
The event will also be attended by Church leaders, policymakers, ethicists, representatives from the stem cell business community and Ministers of Health from around the world, among others. Attendees will take part in a variety of events, including keynote speakers, discussion panels, patient case studies and breakout sessions.
The biopharmaceutical company with a focus on adult stem cell research and regenerative and cell-based therapies, called its collaboration with the Vatican "historical."
NeoStem CEO, Dr. Robin L. Smith said the company hopes to demonstrate "that faith and technology can work together to find ethical solutions to human kind's most ancient problems."
Since starting out as a provider of adult stem cell collection and storage services, New York-based NeoStem has since branched out into cell therapeutics, focused on using stem cells to help cure disease.
In January, the company acquired Progenitor, which has cell therapy manufacturing facilities, as well as processing and storage facilities for stem cells collected from the umbilical cord at birth, located on the east and west coast of the US. Progenitor has performed over 30,000 cell therapy procedures and has processed and stored over 18,000 cell therapy products.
The company also owns a 51% stake in Chinese generic pharmaceutical company Suzhou Erye.